Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial

IMPORTANCE: β-Blockers are prescribed to most patients with heart failure (HF) with a preserved ejection fraction (HFpEF), but their effect on HFpEF remains unclear. OBJECTIVE: To determine the association of β-blocker use with HF hospitalizations and cardiovascular disease (CVD) mortality, overall...

Descripción completa

Detalles Bibliográficos
Autores principales: Silverman, Daniel N., Plante, Timothy B., Infeld, Margaret, Callas, Peter W., Juraschek, Stephen P., Dougherty, Geoff B., Meyer, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902757/
https://www.ncbi.nlm.nih.gov/pubmed/31800067
http://dx.doi.org/10.1001/jamanetworkopen.2019.16598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902757/
https://www.ncbi.nlm.nih.gov/pubmed/31800067
http://dx.doi.org/10.1001/jamanetworkopen.2019.16598

Ejemplares similares